|
Evaxion Biotech A/S (EVAX) DCF Valuation
DK | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Evaxion Biotech A/S (EVAX) Bundle
Whether you're an investor or an analyst, this (EVAX) DCF Calculator is your essential tool for accurate valuation. Preloaded with real data from Evaxion Biotech A/S, you can adjust forecasts and observe the effects in real-time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .1 | .1 | .1 | .1 | .1 | .1 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -11.9 | -16.5 | -24.2 | -22.6 | -21.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | -29319.18 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .1 | .1 | .3 | .6 | .6 | .1 | .1 | .1 | .1 | .1 |
| Depreciation, % | 100 | 100 | 100 | 100 | 843.76 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -12.0 | -16.6 | -24.5 | -23.2 | -22.0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | -30162.94 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 9.6 | 5.8 | 32.2 | 13.2 | 5.6 | .1 | .1 | .1 | .1 | .1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .9 | .0 | .0 | .0 | 1.1 | .1 | .1 | .1 | .1 | .1 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 1472.56 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | -6.9 | -1.9 | -2.5 | .0 | .1 | .1 | .1 | .1 | .1 |
| Inventories, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | .6 | 3.7 | 2.8 | 2.1 | 2.7 | .1 | .1 | .1 | .1 | .1 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 3683.56 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | -.4 | -1.4 | -.3 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | -119.18 | -20 | -20 | -20 | -20 | -20 |
| Tax Rate, % | 3.45 | 3.45 | 3.45 | 3.45 | 3.45 | 3.45 | 3.45 | 3.45 | 3.45 | 3.45 |
| EBITAT | -11.2 | -15.0 | -24.3 | -22.4 | -21.3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -11.4 | -4.4 | -31.2 | -22.3 | -23.7 | -1.6 | .1 | .1 | .1 | .1 |
| WACC, % | 7.2 | 7.04 | 7.6 | 7.44 | 7.43 | 7.34 | 7.34 | 7.34 | 7.34 | 7.34 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 2 | |||||||||
| Present Terminal Value | 1 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | 5 | |||||||||
| Equity Value | -5 | |||||||||
| Diluted Shares Outstanding, MM | 3 | |||||||||
| Equity Value Per Share | -1.86 |
What You Will Get
- Comprehensive EVAX Financials: Access to historical and projected data for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Dynamic calculations for intrinsic value and NPV.
- Scenario Analysis: Evaluate various scenarios to assess Evaxion Biotech's future performance.
- User-Friendly Interface: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive DCF Model: Features both unlevered and levered DCF valuation frameworks tailored for Evaxion Biotech A/S (EVAX).
- WACC Estimator: Ready-to-use Weighted Average Cost of Capital calculator with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital investments, and discount rates as needed.
- Integrated Financial Metrics: Evaluate profitability, leverage, and efficiency ratios specifically for Evaxion Biotech A/S (EVAX).
- Interactive Dashboard and Visuals: Graphical representations that highlight essential valuation indicators for straightforward assessment.
How It Works
- 1. Download the Template: Obtain and open the Excel file containing Evaxion Biotech A/S's preloaded data.
- 2. Adjust Assumptions: Modify essential inputs such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to understand different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making process.
Why Choose This Calculator for Evaxion Biotech A/S (EVAX)?
- Precision: Utilizes real Evaxion financial data for enhanced accuracy.
- Versatility: Allows users to easily test and adjust inputs as needed.
- Efficiency: Eliminate the need to create a DCF model from the ground up.
- Expert-Level: Crafted with the precision and usability expected by CFOs.
- Intuitive: Simple to navigate, suitable for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Accurately estimate Evaxion Biotech A/S’s (EVAX) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Evaxion Biotech A/S (EVAX).
- Consultants: Quickly tailor the template for valuation reports for clients interested in Evaxion Biotech A/S (EVAX).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms, including Evaxion Biotech A/S (EVAX).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies relevant to the biotech sector, including Evaxion Biotech A/S (EVAX).
What the Template Contains
- Preloaded EVAX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.